Viridian Therapeutics Inc (VRDN)

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 MillionMay 6, 2026 11:13 PM
Business Wire Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its upsized underwritten public offering of 7,352,942 shares of its common stock at a public offering price of $17.00 per share (such offering, the “Equity Offering”). Viridian estimates that the aggregate net proceeds from the Convertible Notes Offering and the Equity Offering will be approximately $334.7 million, after deducting underwriting discounts and commissions and Viridian’s estimated offering expenses. In addition, Viridian has granted the underwriters of the Convertible Notes Offering a 30-day option to purchase up to an additional $25.0 million aggregate principal amount of Convertible Notes offered in the Convertible Notes Offering, solely to cover over-allotments and on the same terms and conditions. Viridian also granted the underwriters of the Equity Offering a 30-day option to purchase up to an additional 1,102,941 shares of its common stock, on the same terms and conditions. The Convertible Notes Offering and the Equity Offering are expected to close on May 11, 2026, subject in each case to the satisfaction of customary closing conditions. Neither the closing of the Convertible Notes Offering nor the closing of the Equity Offering is contingent upon the closing of the other offering. The Convertible Notes will be general, unsecured, senior obligations of Viridian and interest will be payable semi-annually in arrears on May 15 and November 15 of each year, beginning on November 15, 2026, at a rate equal to 1.75% per year. The Convertible Notes will mature on May 15, 2032, unless earlier converted, redeemed or repurchased by Viridian. Before February 15, 2032, noteholders may convert their Convertible Notes at their option only in certain circumstances. From, and including, February 15, 2032 until the close of business on the scheduled trading day immediately before the maturity date, noteholders may convert their Convertible Notes at any time at their option. Viridian will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Viridian’s election. The initial conversion rate is 40.5680 shares of Viridian’s common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $24.65 per share of its common stock and represents a conversion premium of approximately 45.0% above the public offering price per share of its common stock in the Equity Offering. If a “make-whole fundamental change” (as defined in the indenture that will govern the Convertible Notes) occurs, then Viridian will in certain circumstances increase the conversion rate for a specified period of time. The Convertible Notes will be redeemable, in whole or in part (subject to certain limitations), at Viridian’s option at any time, and from time to time, on a redemption date on or after May 20, 2030 and on or before the 26th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of its common stock exceeds 130% of the conversion price for the Convertible Notes on (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date Viridian sends the related redemption notice; and (2) the trading day immediately before the date Viridian sends such notice. If a “fundamental change” (as defined in the indenture that will govern the Convertible Notes) occurs, then, subject to a limited exception, noteholders may require Viridian to repurchase their Convertible Notes at a cash repurchase price equal to the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. Viridian intends to use the net proceeds from the Convertible Notes Offering and the Equity Offering to repay all outstanding indebtedness under the Loan and Security Agreement with Hercules Capital, Inc., to fund market expansion studies for its thyroid eye disease (“TED”) franchise, and to advance the research and development of its earlier pipeline, as well as for working capital and other general corporate purposes. Jefferies, Leerink Partners, and Goldman Sachs & Co. LLC are acting as joint book-running managers and LifeSci Capital is acting as lead manager for the Convertible Notes Offering. Jefferies, Leerink Partners, and Goldman Sachs & Co. LLC are acting as joint book-running managers and LifeSci Capital and Wedbush PacGrow are acting as lead managers for the Equity Offering. A registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) and became effective on September 5, 2025. A final prospectus supplement and accompanying base prospectus relating to and describing the terms of each of the Convertible Notes Offering and Equity Offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering will only be made by means of a prospectus, copies of which may be obtained at the SEC’s website at www.sec.gov, or by request to Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022; telephone: 877-821-7388; email: Prospectus_Department@Jefferies.com); Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282 (Tel: 866-471-2526) or by e-mail at prospectus-ny@ny.email.gs.com. About Viridian Therapeutics, Inc. Viridian is a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with autoimmune and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for validated drug targets and disease-driving mechanisms in autoimmune and rare diseases. Viridian is advancing multiple late-stage, anti-insulin-like growth factor-1 receptor (“IGF-1R”) candidates in the clinic for the treatment of patients with TED. The company conducted a pivotal program for veligrotug, including two global phase 3 clinical trials, THRIVE and THRIVE-2, to evaluate its efficacy and safety in patients with active and chronic TED. THRIVE and THRIVE-2 reported positive topline data, meeting their primary endpoints and all secondary endpoints. Viridian is also advancing elegrobart as the potential first subcutaneous autoinjector for the treatment of TED. Viridian is conducting an ongoing pivotal program for elegrobart, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of elegrobart in patients with active and chronic TED. REVEAL-1 and REVEAL-2 reported positive topline data, meeting their primary endpoints and multiple secondary endpoints. In addition to its IGF-1R inhibitor portfolio, Viridian is developing an anti–thyroid-stimulating hormone receptor (“TSHR”) program designed as a potential therapy for TED and Graves’ disease. Viridian is also advancing a novel portfolio of neonatal Fc receptor (“FcRn”) inhibitors, including VRDN-006 and VRDN-008, which have the potential to be developed in multiple autoimmune diseases. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or other similar terms or expressions that concern the company’s expectations, plans and intentions. Forward-looking statements include, without limitation, statements regarding the timing and completion of the offerings on the anticipated terms, or at all; statements regarding the expected net proceeds of the offerings and the anticipated use of proceeds from the offerings; the company’s plans regarding commercial launch activities related to veligrotug and elegrobart and research and development activities; the company’s belief that its product candidates may be best-in-class; and the potential for the company’s novel portfolio of FcRn inhibitors to be developed in multiple autoimmune diseases. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the company’s current beliefs, expectations and assumptions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: market conditions that may affect the timing, terms or conditions of the underwritten public offerings; the company’s successful completion of the underwritten public offerings; the satisfaction of customary closing conditions related to the underwritten public offerings; and other risks and uncertainties identified in the company’s filings with the SEC, including those risks set forth under the caption “Risk Factors” in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 5, 2026, and other subsequent disclosure documents filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. View source version on businesswire.com: https://www.businesswire.com/news/home/20260506078055/en/ Investors Greg Rossino
grossino@viridiantherapeutics.com Media Lisa Lopez
llopez@viridiantherapeutics.com Original: Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 ResultsMay 5, 2026 10:24 AM
IH Market News Regulatory milestones and late-stage clinical progress position the company ahead of a key FDA decision in June.Viridian Therapeutics, Inc. (NASDAQ:VRDN) reported first-quarter 2026 results alongside updates on its pipeline, with a PDUFA decision for veligrotug in thyroid eye disease (TED) set for June 30, 2026. The upcoming regulatory milestone is central for investors, as it could determine near-term commercialization and revenue potential. Key Investor Takeaways Viridian (NASDAQ:VRDN) faces a PDUFA decision on June 30, 2026 for veligrotug, a key catalyst. The company is launch-ready, with commercial infrastructure and supply chain already in place. Positive Phase 3 data for elegrobart supports a future BLA submission in Q1 2027. Cash position of $762M provides funding for pipeline execution and launch activities. Rising SG&A and net losses reflect increased commercialization spending ahead of potential approval. Press Release Overview Viridian reported progress across its thyroid eye disease (TED) portfolio, led by veligrotug, which is under FDA Priority Review with a PDUFA target action date of June 30, 2026. The company stated it has completed hiring of field teams and established supply chain infrastructure in preparation for launch.The company also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency in January 2026, which was accepted for review in February.In addition, Viridian announced positive topline data from two Phase 3 trials—REVEAL-1 and REVEAL-2—for elegrobart (VRDN-003), covering both active and chronic TED. The company plans to submit a Biologics License Application (BLA) in the first quarter of 2027.Beyond TED, the company continues to advance earlier-stage programs, including its TSHR antibody program and FcRn inhibitor portfolio, with additional data and development plans expected later in 2026.Financially, Viridian reported: Cash, cash equivalents, and investments of $762.2 million as of March 31, 2026 R&D expenses of $77.6 million, up slightly year over year SG&A expenses of $38.7 million, rising significantly due to commercial preparation Net loss of $104.9 million for the quarter Why This Matters for Investors The upcoming PDUFA decision represents a critical inflection point. Approval of veligrotug could transition Viridian from a development-stage biotech to a commercial-stage company, which may significantly alter its revenue profile and valuation framework.The company’s readiness for launch suggests it is positioned to move quickly if approval is granted. At the same time, increased operating expenses indicate higher execution risk tied to commercialization.Positive Phase 3 data for elegrobart strengthens the broader TED pipeline, potentially expanding the company’s long-term opportunity in the indication. However, regulatory outcomes and future trial results remain key variables. What to Watch For Next FDA PDUFA decision on veligrotug (June 30, 2026) Updates from the EMA review process Timing and details of elegrobart BLA submission (Q1 2027) Additional data from FcRn and TSHR programs in 2026 Commercial launch execution if approval is granted Conclusion Viridian Therapeutics is approaching a pivotal regulatory event with veligrotug, while continuing to build out a broader TED-focused pipeline. The outcome of the upcoming FDA decision, along with execution on commercialization plans, will likely shape near-term investor sentiment and the company’s strategic trajectory.Viridian Therapeutics stock price Original: PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 Results

Some wild swings in VRDN premarket today.

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-2 Clinical Trial in Chronic Thyroid Eye Disease

Viridian shares plunge despite positive Phase 3 trial resultsMarch 30, 2026 8:46 AM
IH Market News
Shares of Viridian Therapeutics (NASDAQ:VRDN) dropped about 40% on Monday after the company released topline data from its Phase 3 REVEAL-1 study of elegrobart in patients with active thyroid eye disease, even though the treatment met its primary endpoint.The trial produced a highly statistically significant treatment effect. Patients receiving elegrobart every four weeks (Q4W) and every eight weeks (Q8W) achieved proptosis responder rates of 54% and 63%, respectively, compared with 18% in the placebo group at week 24. In the Q4W dosing group, 51% of patients experienced complete resolution of diplopia, versus 16% among those receiving placebo.The REVEAL-1 study enrolled 132 participants, who were evenly randomized into three groups: elegrobart Q4W, elegrobart Q8W and placebo. The trial met its primary endpoint of proptosis responder rate in the Q4W arm with strong statistical significance (p

VRDN more upside possible

Touched 20s today. Maybe it will stay above 20 tomorrow

LOW 20'S BY WEEKEND IMO !!!
GOOD LUCK

Good news. I don't think that this is merely a one-day runner.

BTIG RESEARCH ADJUST PRICE TARGET TO 56 FROM 46; STRONG BUY !!

Over 15 and having a good day today

VRDN under $15

I put into it a lot of $
423 shares!

It just doesn't want to move above $18
Yet, it's not diving much either.
What do you think at this point? Sell temporarily and by later low?
My average is too high @17.76 !

Viridian Therapeutics, Inc., formerly Miragen Therapeutics, Inc., is a biotechnology company. The Company is engaged in developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications. Its lead candidate, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody (mAb) that is under development for thyroid eye disease (TED). The Company's TED pipeline also includes VRDN-002 and VRDN-003. Its other programs include VRDN-004, which is under development for undisclosed rare orphan disease, and VRDN-005, which is under development for tick-borne disease (TBD). The Company also out licenses its programs.